A public health value-based healthcare paradigm for HIV.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
02 Jan 2022
Historique:
received: 25 06 2021
accepted: 01 12 2021
entrez: 3 1 2022
pubmed: 4 1 2022
medline: 5 1 2022
Statut: epublish

Résumé

HIV patients face considerable acute and chronic healthcare needs and battling the HIV epidemic remains of the utmost importance. By focusing on health outcomes in relation to the cost of care, value-based healthcare (VBHC) proposes a strategy to optimize quality of care and cost-efficiency. Its implementation may provide an answer to the increasing pressure to optimize spending in healthcare while improving patient outcomes. This paper describes a pragmatic value-based healthcare framework for HIV care. A value-based HIV healthcare framework was developed during a series of roundtable discussions bringing together 16 clinical stakeholder representatives from the Belgian HIV reference centers and 2 VBHC specialists. Each round of discussions was focused on a central question translating a concept or idea to the next level of practical implementation: 1) how can VBHC principles be translated into value-based HIV care drivers; 2) how can these value-based HIV care divers be translated into value-based care objectives and activities; and 3) how can value-based HIV care objectives and activities be translated into value-based care indicators. Value drivers were linked to concrete objectives and activities using a logical framework approach. Finally, specific, measurable, and acceptable structure, process and outcomes indicators were defined to complement the framework. Our framework identifies 4 core value areas where HIV care would benefit most from improvements: Prevention, improvement of the cascade of care, providing patient-centered HIV care and sustaining a state-of-the-art HIV disease management context. These 4 core value areas were translated into 12 actionable core value objectives. For each objective, example activities were proposed. Indicators are suggested for each level of the framework (outcome indicators for value areas and objectives, process indicators for suggested activities). This framework approach outlines how to define a patient- and public health centered value-based HIV care paradigm. It proposes how to translate core value drivers to practical objectives and activities and suggests defining indicators that can be used to track and improve the framework's implementation in practice.

Sections du résumé

BACKGROUND BACKGROUND
HIV patients face considerable acute and chronic healthcare needs and battling the HIV epidemic remains of the utmost importance. By focusing on health outcomes in relation to the cost of care, value-based healthcare (VBHC) proposes a strategy to optimize quality of care and cost-efficiency. Its implementation may provide an answer to the increasing pressure to optimize spending in healthcare while improving patient outcomes. This paper describes a pragmatic value-based healthcare framework for HIV care.
METHODS METHODS
A value-based HIV healthcare framework was developed during a series of roundtable discussions bringing together 16 clinical stakeholder representatives from the Belgian HIV reference centers and 2 VBHC specialists. Each round of discussions was focused on a central question translating a concept or idea to the next level of practical implementation: 1) how can VBHC principles be translated into value-based HIV care drivers; 2) how can these value-based HIV care divers be translated into value-based care objectives and activities; and 3) how can value-based HIV care objectives and activities be translated into value-based care indicators. Value drivers were linked to concrete objectives and activities using a logical framework approach. Finally, specific, measurable, and acceptable structure, process and outcomes indicators were defined to complement the framework.
RESULTS RESULTS
Our framework identifies 4 core value areas where HIV care would benefit most from improvements: Prevention, improvement of the cascade of care, providing patient-centered HIV care and sustaining a state-of-the-art HIV disease management context. These 4 core value areas were translated into 12 actionable core value objectives. For each objective, example activities were proposed. Indicators are suggested for each level of the framework (outcome indicators for value areas and objectives, process indicators for suggested activities).
CONCLUSIONS CONCLUSIONS
This framework approach outlines how to define a patient- and public health centered value-based HIV care paradigm. It proposes how to translate core value drivers to practical objectives and activities and suggests defining indicators that can be used to track and improve the framework's implementation in practice.

Identifiants

pubmed: 34974833
doi: 10.1186/s12913-021-07371-7
pii: 10.1186/s12913-021-07371-7
pmc: PMC8722062
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13

Informations de copyright

© 2021. The Author(s).

Références

Lancet Infect Dis. 2015 Jul;15(7):810-8
pubmed: 26070969
Harv Bus Rev. 2016 Jul-Aug;94(7-8):88-98, 100, 134
pubmed: 27526565
BMC Health Serv Res. 2020 Aug 27;20(1):805
pubmed: 32847579
N Engl J Med. 2016 Jul 21;375(3):205-7
pubmed: 27468057
BMJ. 2017 Jan 27;356:j437
pubmed: 28130219
Qual Life Res. 2019 Oct;28(10):2685-2694
pubmed: 31098796
Acta Clin Belg. 2018 Feb;73(1):54-67
pubmed: 28673201
J R Soc Med. 2016 Dec;109(12):453-458
pubmed: 27923898
BMC Geriatr. 2018 Apr 20;18(1):99
pubmed: 29678160
BMJ. 1995 Aug 5;311(7001):376-80
pubmed: 7640549
N Engl J Med. 2016 Feb 11;374(6):504-6
pubmed: 26863351
N Engl J Med. 2007 Feb 1;356(5):515-7
pubmed: 17259445
BMC Health Serv Res. 2017 Feb 28;17(1):169
pubmed: 28241823
Sociol Health Illn. 2018 Sep;40(7):1113-1126
pubmed: 29675960
BMC Health Serv Res. 2013 Jun 28;13:236
pubmed: 23809537
Health Policy. 2005 Dec;75(1):59-73
pubmed: 16298229
N Engl J Med. 2010 Dec 23;363(26):2477-81
pubmed: 21142528
Lancet. 2013 Jul 20;382(9888):200-1
pubmed: 23878859
Milbank Mem Fund Q. 1966 Jul;44(3):Suppl:166-206
pubmed: 5338568

Auteurs

Sebastian Vermeersch (S)

Hict, Ottergemsesteenweg-Zuid 808 B/354, 9000, Gent, Belgium. Sebastian.Vermeersch@Hict.be.

Rémy P Demeester (RP)

HIV Reference Centre, University Hospital of Charleroi, Charleroi, Belgium.

Nathalie Ausselet (N)

Department of Infectious Diseases, CHU UCL Namur, Namur, Belgium.

Steven Callens (S)

Department General Internal Medicine, Ghent University Hospital, Ghent, Belgium.

Paul De Munter (P)

Department of Microbiology Immunology, Transplantation and HIV Reference Centre, University Hospital Leuven, Leuven, Belgium.

Eric Florence (E)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Jean-Christophe Goffard (JC)

HIV Reference Centre, Internal Medicine, C.U.B. Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Sophie Henrard (S)

HIV Reference Centre, Internal Medicine, C.U.B. Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Patrick Lacor (P)

HIV Reference Centre, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Peter Messiaen (P)

Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium.

Agnès Libois (A)

Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Lucie Seyler (L)

HIV Reference Centre, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Françoise Uurlings (F)

HIV Reference Centre, Infectious Diseases Department, Liège University Hospital, Liege, Belgium.

Stefaan J Vandecasteele (SJ)

Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge Oostende AV, Brugge, Belgium.

Eric Van Wijngaerden (E)

Department of Microbiology Immunology, Transplantation and HIV Reference Centre, University Hospital Leuven, Leuven, Belgium.

Jean-Cyr Yombi (JC)

Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint Luc, Brussels, Belgium.

Lieven Annemans (L)

Department of Public Health, Ghent University, Ghent, Belgium.

Stéphane De Wit (S)

Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH